krebsliga_aargaukrebsliga_baselkrebsliga_bernkrebsliga_bern_dekrebsliga_bern_frkrebsliga_freiburgkrebsliga_freiburg_dekrebsliga_freiburg_frkrebsliga_genfkrebsliga_glaruskrebsliga_graubuendenkrebsliga_jurakrebsliga_liechtensteinkrebsliga_neuenburgkrebsliga_ostschweizkrebsliga_schaffhausenkrebsliga_schweiz_dekrebsliga_schweiz_fr_einzeiligkrebsliga_schweiz_frkrebsliga_schweiz_itkrebsliga_solothurnkrebsliga_stgallen_appenzellkrebsliga_tessinkrebsliga_thurgaukrebsliga_waadtkrebsliga_wallis_dekrebsliga_wallis_frkrebsliga_zentralschweizkrebsliga_zuerichkrebsliga_zug
Ligue contre le cancerAccès spécialistesQualité du dépistage et du traitement du cancer du seinLabel de qualité pour les centres du seinOpen and planned studies on breast cancerLabel de qualité pour les centres du sein

Open and planned studies on breast cancer

Certified breast centres are requested to recruit patients in prospective clinical trials.

Currently open and planned studies, coordinated by the following organisations:

Please send information about new studies to: q-label@swisscancer.ch

open studies

EORTC 1401
Management of low risk ductal carcinoma in situ (low-risk DCIS): a randomized, multicentre, non-inferiority trial, between standard therapy approach versus active surveillance.

EORTC-1502-BCG PHYTIA
A phase II study of Palbociclib plus Fulvestrant vs Fulvestrant plus Placebo for pretreated patients with ER+/HER2- metastatic Breast Cancer; Palbociclib in molecularly characterized ER-Positive/HER2 negative metastatic Breast Study 

IBCSG 48-14 POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy.

IBCSG 51-14 AURORA
Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

SAKK 24/14
Efficacy of a new kind of chemotherapy for the treatment of breast cancer

IBCSG 50-14 OLYMPIA
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

SAKK 96/12
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

SAKK 65/16
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

SAKK 23/16
Tailored AXIllary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)

IBSCG 55-17 TOUCH
To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

SAKK 95/17
Activity Program During Aromatase Inhibitor Therapy

Bureau du label de qualité

Ligue suisse contre le cancer
Effingerstrasse 40
Case postale 8219
3001 Berne
label_qualite@liguecancer.ch